B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical advances in hematology & oncology : H&O

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 27057669
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.

  2015cited by this paper
• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

  2015cited by this paper
• Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

  2015cited by this paper
• The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

  2015cited by this paper
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  2015cited by this paper
• An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.

  2015cited by this paper
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014cited by this paper
• Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

  2014cited by this paper
• Targetable activating mutations are very frequent in GCB and ABC diffuse large B‐cell lymphoma

  2014cited by this paper
• The bruton tyrosine kinase inhibitor ibrutinib (PCI‐32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

  2014cited by this paper
• The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer

  2014cited by this paper
• Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

  2014cited by this paper
• Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

  2014cited by this paper
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Targeting pathological B cell receptor signalling in lymphoid malignancies

  2013cited by this paper
• The BAFF Receptor Transduces Survival Signals by Co-opting the B Cell Receptor Signaling Pathway

  2013cited by this paper
• A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient

  2013cited by this paper
• PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013cited by this paper
• Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

  2013cited by this paper
• Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

  2012cited by this paper
• Pathogenesis of human B cell lymphomas.

  2012cited by this paper
• Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.

  2012cited by this paper
• Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

  2012cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

  2012cited by this paper
• Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

  2012cited by this paper
• Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

  2012cited by this paper
• Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

  2012cited by this paper
• The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

  2012cited by this paper
• Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

  2012cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

  2011cited by this paper
• Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling

  2011cited by this paper
• Dynamic cortical actin remodeling by ERM proteins controls BCR microcluster organization and integrity

  2011cited by this paper
• Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases.

  2011cited by this paper
• The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

  2011cited by this paper
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

  2011cited by this paper
• An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

  2010cited by this paper
• The tipping points in the initiation of B cell signalling: how small changes make big differences

  2010cited by this paper
• Oligomeric organization of the B-cell antigen receptor on resting cells

  2010cited by this paper
• The SYK tyrosine kinase: a crucial player in diverse biological functions

  2010cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.

  2009cited by this paper
• B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

  2009cited by this paper
• Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

  2009cited by this paper
• Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

  2009cited by this paper
• PI3 kinase signals BCR-dependent mature B cell survival.

  2009cited by this paper
• Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

  2009cited by this paper
• VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

  2009cited by this paper
• Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

  2008cited by this paper
• B lymphocytes: how they develop and function.

  2008cited by this paper
• The B Cell Antigen Receptor and Overexpression of MYC Can Cooperate in the Genesis of B Cell Lymphomas

  2008cited by this paper
• A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

  2008cited by this paper
• Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.

  2008cited by this paper
• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008cited by this paper
• SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

  2008cited by this paper
• The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.

  2008cited by this paper
• Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

  2007cited by this paper
• ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.

  2007cited by this paper
• A loss-of-function RNA interference screen for molecular targets in cancer

  2006cited by this paper
• Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

  2006cited by this paper
• Somatic hypermutation and VH gene usage in hairy cell leukaemia

  2006cited by this paper
• B lymphocytes in humans express ZAP‐70 when activated in vivo

  2006cited by this paper
• Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

  2006cited by this paper
• ITAM-mediated tonic signalling through pre-BCR and BCR complexes

  2006cited by this paper
• B-cell kinetics in humans: rapid turnover of peripheral blood memory cells.

  2005cited by this paper
• ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype

  2005cited by this paper
• Mechanisms of B-cell lymphoma pathogenesis

  2005cited by this paper
• Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

  2005cited by this paper
• Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity.

  2005cited by this paper
• B cell antigen receptor signaling 101.

  2004cited by this paper
• Survival of Resting Mature B Lymphocytes Depends on BCR Signaling via the Igα/β Heterodimer

  2004cited by this paper
• Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia

  2004cited by this paper
• Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer.

  2004cited by this paper
• Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch.

  2004cited by this paper
• The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2

  2003cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110δ in Signaling by the B-Cell Receptor Complex

  2002cited by this paper
• Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop.

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Monomeric and oligomeric complexes of the B cell antigen receptor.

  2000cited by this paper

• Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care.

  2025cites this paper
• Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies

  2024cites this paper
• CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies.

  2024cites this paper
• SARS‐CoV‐2 infection is not associated with the emergence of monoclonal gammopathies

  2024cites this paper
• Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.

  2024cites this paper
• Recent advances in canonical versus non-canonical Ca2+-signaling-related anti-apoptotic Bcl-2 functions and prospects for cancer treatment.

  2024cites this paper
• Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

  2023cites this paper
• Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma

  2022cites this paper
• Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282.

  2022cites this paper
• 5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia.

  2022cites this paper
• Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay

  2022cites this paper
• Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway

  2021cites this paper
• Deciphering genes associated with diffuse large B-cell lymphoma with lymphomatous effusions: A mutational accumulation scoring approach

  2021cites this paper
• How is Aurora Kinase A Expression Altered in Chronic Lymphocytic Leukemia

  2020cites this paper
• B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia

  2020cites this paper
• Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.

  2020cites this paper
• Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?

  2019cites this paper
• The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

  2019cites this paper
• The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL)

  2019cites this paper
• Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes

  2018cites this paper
• Holding All the CARDs: How MALT1 Controls CARMA/CARD-Dependent Signaling

  2018cites this paper
• Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

  2018cites this paper
• Conditional Selection of B Cells in Mice With an Inducible B Cell Development

  2018cites this paper
• The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study

  2018cites this paper
• Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment

  2018cites this paper
• The possible role of maintenance treatment for primary central nervous system lymphoma.

  2018cites this paper
• Paper de la via de senyalització del receptor de cèl·lules B (BCR) en la interacció entre les cèl·lules de leucèmia limfàtica crònica i el microambient tumoral

  2018cites this paper
• Ectopic Lck expression in CLL demarcates intratumoral subpopulations with aberrant B-cell receptor signaling.

  2018cites this paper
• Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

  2017cites this paper
• JPET # 238022 1 Dual Inhibition of Bruton ’ s Tyrosine Kinase and Phosphoinositide-3-Kinase p 110 δ as a Therapeutic Approach to Treat Non-Hodgkin ’ s B cell Malignancies

  2017influential citation
• Dual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies

  2017cites this paper